Subcutaneous immunoglobulin replacement therapy with Hizentra® is safe and effective in two infants.

Journal Article (Journal Article)

Hizentra® is a 20% liquid IgG product approved for subcutaneous administration in adults and children greater than 2 years of age. We report two infants less than 2 years in which administration of Hizentra® was safe and effective.

Full Text

Duke Authors

Cited Authors

  • Gallagher, JL; Patel, NC

Published Date

  • June 2012

Published In

Volume / Issue

  • 32 / 3

Start / End Page

  • 474 - 476

PubMed ID

  • 22228569

Electronic International Standard Serial Number (EISSN)

  • 1573-2592

Digital Object Identifier (DOI)

  • 10.1007/s10875-011-9645-0

Language

  • eng

Conference Location

  • Netherlands